Ireland’s Cosmo Pharma claimed FDA approval for its traveller’s diarrhoea drug Aemcolo, which some analysts say could be a big threat to a rival drug sold by Bausch Health’s Salix unit.

CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group with a current market capitalization of $19.54 million, has acquired exclusive rights to two patented anticancer drugs ...